US Biosimilar Assets Portfolio — Teva IM Repository

◆

Total Biosimilar Assets

0

⚗

Clinical Development

0

📄

BLA Filed

0

✓

Approval & Marketed

0

?

Undisclosed

0

In-Line vs Pipeline Split

In-Line Pipeline

Asset Count by Therapeutic Area

Partnership & Collaboration

Flow: Company → Commercial Partner → Manufacturing Partner (link width = number of assets). Showing top nodes by asset count; use filters above to trace a specific company or partner.

Company Portfolio Size — asset count by company, colored by dominant stage

Executive Insights

◆

Total Biosimilar Assets

0

⚗

Clinical Development

0

📄

BLA Filed

0

✓

Approval & Marketed

0

?

Undisclosed

0

Asset Count by Stage

Company Count by Stage

In-Line Pipeline

Biosimilar Launch Timelines

Molecule	Reference Product	Company Name	Asset Name	Stage	Approval Date (US)	Launch Date (US)

Biosimilar Launch Entry Waves

Visualizing historical launch surges and projected pipeline entries by year

Molecule Competitive Landscape — asset count by molecule, colored by number of competing companies

Executive Insights

Portfolio Simulation Sandbox

Adjust clinical success confidence and market share assumptions to dynamically model Teva's risk-adjusted expected pipeline value.

Clinical Success Rate 70%

Phase I / II (20%)Approved (100%)

Projected Peak Market Share 15%

Niche player (5%)Market Leader (40%)

Risk-Adjusted Expected Value

$0.0M

Sum of (addressable market × success rate × peak share) across modeled assets — edit market estimates in the panel on the right.

Strategic Partnership Highlight

Risk-Adjusted Expected Pipeline Value Breakdown — peak modeling, editable

Addressable market ($M) values below are editable illustrative placeholders for scenario modeling — replace with your own market intelligence for accurate output.

Asset	Molecule (Ref. Product)	Stage	Addressable Mkt ($M)	Risk-Adj. Value

Head-to-Head Overlap Race Comparison

Molecules where Teva and a selected competitor both have tracked assets

Molecule (Brand)	Teva Status	Competitor Status

US Assets Portfolio by Player

In-Line vs Pipeline Split

Asset Count by Therapeutic Area

Partnership & Collaboration

Company Portfolio Size — asset count by company, colored by dominant stage

Executive Insights

Asset Count by Stage

Company Count by Stage

Biosimilar Launch Timelines

Biosimilar Launch Entry Waves

Molecule Competitive Landscape — asset count by molecule, colored by number of competing companies

Executive Insights

Teva Corporate Portfolio Center

Portfolio Simulation Sandbox

Strategic Partnership Highlight

Risk-Adjusted Expected Pipeline Value Breakdown — peak modeling, editable

Head-to-Head Overlap Race Comparison